Argentina oversees bidding for cancer drugs worth 193 million pesos
Argentina
30 enero 2019

On January 28, the executive branch granted drug companies the purchase of 193 million pesos’ worth of oncological medicines. This was split among 14 companies, with Elea Phoenix gaining the largest share (51 million pesos or 1.3 million dollars), followed by IMA (with 29 million pesos or 778 thousand dollars). Bids received by other companies, including Roche, were rejected by the executive. However, they have until February 4th to submit a reconsideration appeal requesting their bids be reevaluated.

The objective of the bid is to ensure the purchase of oncology drugs necessary to maintaining an “adequate” stock, in order to meet the needs of patients served under the Public Health System and through the National Bank of Oncology Drugs.

A resolution published in the Official Gazette Monday 28 gives drug makers the chance to challenge the contracting decisions of the government’s executive. It stipulates a period of 10 working days to file an appeal for reconsideration. It also allows for the possibility of making a direct hierarchical appeal, to be completed within 15 working days.

Noticias Relacionadas
wefeqwf